Altered dna binding and amplification of human breast cancer suppressor gene BRCA1 induced by a novel antitumor compound, [Ru(η 6-p-phenylethacrynate)Cl 2(pta)]

International Journal of Molecular Sciences

Volumn 13, Issue 10, 2012, Pages 13183-13202

  Chakree, Korawan ^a   Ovatlarnporn, Chitchamai ^a   Dyson, Paul J ^b   Ratanaphan, Adisorn ^a  

^a PRINCE OF SONGKLA UNIVERSITY   (Thailand)

^b EPFL   (Switzerland)

Author keywords

BRCA1; DNA adducts; DNA amplification; Etharapta; Tumor suppressor gene

Indexed keywords

ALANINE; ANTINEOPLASTIC AGENT; CISPLATIN; CYSTEINE; GLYCINE; RUTHENIUM (ETA6 4 PHENYLETHACRYNATE)CHLORIDE 1,3,5 TRIAZA 7 PHOSPHATRICYCLO [3.3.1.1] DECANE COMPLEX; RUTHENIUM ARENE 1,3,5 TRIAZA 7 PHOSPHATRICYCLO [3.3.1.1] DECANE COMPLEX; RUTHENIUM COMPLEX; THREONINE; UNCLASSIFIED DRUG; BRCA1 PROTEIN; DICHLORO(4-CYMENE)(1,3,5-TRIAZA-7-PHOSPHATRICYCLO(3.3.1.1)DECANE)RUTHENIUM(II); DNA; DNA ADDUCT; ORGANOMETALLIC COMPOUND; PROTEIN BINDING;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CELL ISOLATION; CELL VIABILITY; COLON ADENOCARCINOMA; CONCENTRATION RESPONSE; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; DNA BINDING; DNA MODIFICATION; DNA SEQUENCE; DRUG CYTOTOXICITY; DRUG DNA INTERACTION; DRUG EFFECT; DRUG STRUCTURE; GENE AMPLIFICATION; GENE INTERACTION; GENE STRUCTURE; HUMAN; HUMAN CELL; MOLECULAR STABILITY; THERMOSTABILITY; TUMOR SUPPRESSOR GENE; BREAST TUMOR; CHEMISTRY; DNA ADDUCT; DNA DAMAGE; DRUG EFFECTS; FEMALE; HT 29 CELL LINE; MCF 7 CELL LINE; METABOLISM; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; PATHOLOGY; TEMPERATURE;

ANTINEOPLASTIC AGENTS; BASE SEQUENCE; BRCA1 PROTEIN; BREAST NEOPLASMS; DNA; DNA ADDUCTS; DNA DAMAGE; FEMALE; HT29 CELLS; HUMANS; MCF-7 CELLS; MOLECULAR SEQUENCE DATA; ORGANOMETALLIC COMPOUNDS; PROTEIN BINDING; TEMPERATURE;

EID: 84867810726     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms131013183     Document Type: Article

References (58)

1. Rosenberg, B.; van Camp, L.; Krigas, T. Inhibition of division in Escherichia coli by electrolysis products from a platinum electrode. Nature 1965, 205, 698-699.
2. Rosenberg, B.; van Camp, L.; Trosko, J.E.; Mansour, V.H. Platinum compounds: A new class of potent antitumor agents. Nature 1969, 222, 385-386.
3. Keppler, B.K. Metal Complexes in Cancer Chemotherapy, 1st ed.; VCH Publishers: New York, NY, USA, 1993; pp. 1-8.
4. Orvig, C.; Abrams, M.J. Medicinal inorganic chemistry: Introduction. J. Chem. Rev. 1999, 99, 2202-2203.
5. Eastman, A. Reevaluation of interaction of cis-dichloro(ethylenediamine)-platinum(II) with DNA. Biochemistry 1986, 25, 3912-3915.
6. Fichtinger-Schepman, A.M.J.; van Oosterom, A.T.; Lohman, P.H.M.; Berends, F. cis-Diamminedichloroplatinum(II)-induced DNA adducts in peripheral leukocytes from seven cancer patients. Cancer Res. 1987, 47, 3000-3004.
7. Wong, E.; Giandomenico, C.M. Current status of platinum-based antitumor drugs. Chem. Rev. 1999, 99, 2451-2466.
8. Holler, E. Mechanism of Action of Tumor-Inhibiting Metal Complexes. In Metal Complexes in Cancer Chemotherapy, 1st ed.; Keppler, B.K., Ed.; VCH Publishers: New York, NY, USA, 1993; pp. 39-71.
9. Wernyj, R.P.; Morin, P.J. Molecular mechanisms of platinum resistance: Still searching for the Achilles' heel. Drug Resist. Updat. 2004, 7, 227-232.
10. Scolaro, C.; Bergamo, A.; Brescacin, L.; Delfino, R.; Cocchietto, M.; Laurenczy, G.; Geldbach, T.J.; Sava, G.; Dyson, P.J. In vitro and in vivo evaluation of ruthenium(II)-arene pta complexes. J. Med. Chem. 2005, 48, 4161-4171.
11. Allardyce, C.S.; Dyson, P.J. Ruthenium in medicine: Current clinical uses and future prospects. Platinum Metals Rev. 2001, 45, 62-69.
12. Ang, W.H.; Dyson, P.J. Classical and non-classical ruthenium-based anticancer drugs: Towards targeted chemotherapy. Eur. J. Inorg. Chem. 2006, 2006, 4003-4018.
13. Groessl, M.; Tsybin, Y.; Hartinger, C.; Keppler, B.K.; Dyson, P.J. Ruthenium versus platinum: Interactions of anticancer metallodrugs with duplex oligonucleotides characterized by electrospray ionisation mass spectrometry. J. Biol. Inorg. Chem. 2010, 15, 677-688.
14. Dorcier, A.; Hartinger, C.G.; Scopelliti, R.; Fish, R.H.; Keppler, B.K.; Dyson, P.J. Studies on the reactivity of organometallic Ru-, Rh- and Os-pta complexes with DNA model compounds. J. Inorg. Biochem. 2008, 102, 1066-1076.
15. Allardyce, C.S.; Dyson, P.J.; Ellis, D.J.; Heath, S.L. [Ru(eta(6)-p-cymene)Cl2(pta)] (pta=1,3,5-triaza-7-phosphatricyclo[3.3.1.1]decane): A water soluble compound that exhibits pH dependent DNA binding providing selectivity for diseased cells. Chem. Commun. 2001, 1396-1397.
16. Groessl, M.; Hartinger, C.G.; Dyson, P.J.; Keppler, B.K. CZE-ICP-MS as a tool for studying the hydrolysis of ruthenium anticancer drug candidates and their reactivity towards the DNA model compound dGMP. J. Inorg. Biochem. 2008, 102, 1060-1065.
17. Bergamo, A.; Masi, A.; Dyson, P.J.; Sava, G. Modulation of the metastatic progression of breast cancer with an organometallic ruthenium compound. Int. J. Oncol. 2008, 33, 1281-1289.
18. Chatterjee, S.; Kundu, S.; Bhattacharyya, A.; Hartinger, C.G.; Dyson, P.J. The ruthenium(II)-arene compound RAPTA-C induces apoptosis in EAC cells through mitochondrial and p53-JNK pathways. J. Biol. Inorg. Chem. 2008, 13, 1149-1155.
19. Ang, W.H.; de Luca, A.; Chapuis-Bernasconi, C.; Juillerat-Jeanneret, L.; Lo Bello, M.; Dyson, P.J. Organometallic ruthenium inhibitors of glutathione-S-transferase P1-1 as anticancer drugs. ChemMedChem 2007, 2, 1799-1806.
20. Huen, M.S.Y.; Sy, S.M.H.; Chen, J. BRCA1 and its toolbox for the maintenance of genome integrity. Nat. Rev. Mol. Cell. Biol. 2010, 11, 138-148.
21. O'Donovan, P.J.; Livingston, D.M. BRCA1 and BRCA2: Breast/ovarian cancer susceptibility gene products and participants in DNA double-strand break repair. Carcinogenesis 2010, 31, 961-967.
22. Miki, Y.; Swensen, J.; Shattuck-Eidens, D.; Futreal, P.A.; Harshman, K.; Tavtigian, S.; Liu, Q.; Cochran, C.; Bennett, L.M.; Ding, W.; et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994, 266, 66-71.
23. Ratanaphan, A.; Temboot, P.; Dyson, P.J. In vitro ruthenation of human breast cancer suppressor gene1 (BRCA1) by the antimetastasis compound RAPTA-C and its analogue carboRAPTA-C. Chem. Biodivers. 2010, 7, 1290-1302.
24. Ratanaphan, A.; Wasiksiri, S.; Canyuk, B.; Prasertsan, P. Cisplatin-damaged BRCA1 exhibits altered thermostability and transcriptional transactivation. Cancer Biol. Ther. 2009, 8, 890-898.
25. Hartinger, C.G.; Timerbaev, A.R.; Keppler, B.K. Capillary electrophoresis in anti-cancer metallodrug research: Advances and future challenges. Electrophoresis 2003, 24, 2023-2037.
26. Mei, W.J.; Liu, J.; Chao, H.; Ji, L.N.; Li, A.X.; Liu, J.Z. DNA-binding and cleavage studies of a novel porphyrin ruthenium mixed complex [MPyTPP-Ru(pip)2Cl]+. Transit. Met. Chem. 2003, 28, 852-857.
27. Arjmand, F.; Mohani, B.; Ahmad, S. Synthesis, antibacterial, antifungal activity and interaction of CT-DNA with a new benzimidazole derived Cu(II) complex. Eur. J. Med. Chem. 2005, 40, 1103-1110.
28. Mei, W.J.; Liu, Y.X.; Liu, J.; Li, J.; Zheng, K.C.; Ji, L.N. Synthesis, characterization and DNA-binding properties of mixed porphyrin-polypyridyl ruthenium(II) complexes. Transit. Met. Chem. 2005, 30, 82-88.
29. Lu, X.L.; Zhang, L.; Lou, J.D.; Yan, J.; Nong, P.-S.; Chen, X.-H.; Yang, J.-J.; Gao, M. Synthesis, characterization and DNA binding studies of two cyclopentadienyl ruthenium(II) complexes with amino acid ligands. Transit. Met. Chem. 2010, 35, 513-519.
30. Ang, W.H.; Casini, A.; Sava, G.; Dyson, P.J. Organometallic ruthenium-based antitumor compounds with novel modes of action. J. Organomet. Chem. 2011, 696, 989-998.
31. Messori, L.; Casini, A.; Vullo, D.; Haroutiunian, S.G.; Dalian, E.B.; Orioli, P. Effects of two representative antitumor ruthenium(III) complexes on thermal denaturation profiles of DNA. Chim. Acta 2000, 303, 283-286.
32. Grover, N.; Welch, T.W.; Fairley, T.A.; Cory, M.; Thorp, H.H. Covalent binding of aquaruthenium complexes to DNA. Inorg. Chem. 1994, 33, 3544-3548.
33. Ratanaphan, A.; Canyuk, B.; Wasiksiri, S.; Mahasawat, P. In vitro platination of human breast cancer suppressor gene 1 (BRCA1) by the anticancer drug carboplatin. Biochim. Biophys. Acta 2005, 1725, 145-151.
34. Grimaldi, K.A.; Bingham, J.P.; Souhami, R.L.; Hartley, J.A. DNA damage by anticancer agents and its repair: Mapping in cells at the subgene level with quantitative polymerase chain reaction. Anal. Biochem. 1994, 222, 236-242.
35. Jennerwein, M.M.; Eastman, A. A polymerase chain reaction-based method to detect cisplatin adducts in specific genes. Nucleic Acids Res. 1991, 19, 6209-6214.
36. Govan, H.L.; Valles-Ayoub, Y.; Braun, J. Fine-mapping of DNA damage and repair in specific genomic segments. Nucleic Acids Res. 1990, 18, 3823-3830.
37. Honma, M.; Hayashi, M.; Hackman, P.; Sofuni, T. Chlorambucil-induced structural changes in the gpt gene of AS 52 cells. Mutat. Res. Toxicol. Environ. Mutagen. 1997, 389, 199-205.
38. Hickson, I.; Fairbairn, L.J.; Chinnasamy, N.; Lashford, L.S.; Thatcher, N.; Margison, G.P.; Dexter, T.M.; Rafferty, J.A. Chemoprotective gene transfer I: Transduction of human haemopoietic progenitors with O6-benzylguanine-resistant O6 alkylating-DNA alkyltransferase attenuates the toxic effects of O6-alkylating agents in vitro. Gene Ther. 1998, 5, 835-841.
39. Yuh, S.H.; Tibudan, M.; Hentosh, P. Analysis of 2-chloro-2'-deoxy-adenosine incorporation into cellular DNA by quantitative polymerase chain reaction. Anal. Biochem. 1998, 262, 1-8.
40. Ang, W.H. Development of organometallic ruthenium(II) anticancer (RAPTA) drugs. Chimia 2007, 61, 140-142.
41. Ang, W.H.; Parker, L.J.; de Luca, A.; Juillerat-Jeanneret, L.; Morton, C.J.; Lo Bello, M.; Parker, M.W.; Dyson, P.J. Rational design of an organometallic glutathione transferase inhibitor. Angew. Chem. Int. Ed. 2009, 48, 3854-3857.
42. Mahajan, S.; Atkins, W.M. The chemistry and biology of inhibitors and pro-drugs targeted to glutathione S-transferases. Cell. Mol. Life Sci. 2005, 62, 1221-1233.
43. Van Iersel, M.L.P.S.; Ploemen, J.P.H.T.M.; Struik, I.; van Amersfoort, C.; Keyzer, A.E.; Schefferlie, J.G.; van Bladeren, P.J. Inhibition of glutathione S-transferase activity in human melanoma cells by α,β-unsaturated carbonyl derivatives. Effects of acrolein, cinnamaldehyde, citral, crotonaldehyde, curcumin, ethacrynic acid, and trans-2-hexenal. Chem. Biol. Interact. 1996, 102, 117-132.
44. Lo, H.W.; Ali-Osman, F. Genetic polymorphism and function of glutathione S-transferases in tumor drug resistance. Curr. Opin. Pharmacol. 2007, 7, 367-374.
45. Casini, A.; Hartinger, C.; Nazarov, A.; Dyson, P.J. Organometallic antitumour agents with alternative modes of action. Top. Organomet. Chem. 2010, 32, 57-80.
46. Chatterjee, S.; Biondi, I.; Dyson, P.J.; Bhattacharyya, A. A bifunctional organometallic ruthenium drug with multiple modes of inducing apoptosis. J. Biol. Inorg. Chem. 2011, 16, 715-724.
47. Meggers, E.; Atilla-Gokcumen, G.E.; Grundler, K.; Frias, C.; Prokop, A. Inert ruthenium half-sandwich complexes with anticancer activity. Dalton Trans. 2009, doi:10.1039/B917792B.
48. Adler, V.; Yin, Z.; Fuchs, S.Y.; Benezra, M.; Rosario, L.; Tew, K.D.; Pincus, M.R.; Sardana, M.; Henderson, C.J.; Wolf, C.R. et al. Regulation of JNK signaling by GSTp. EMBO J. 1999, 18, 1321-1334.
49. Wu, B.; Ong, M.S.; Groessl, M.; Adhireksan, Z.; Hartinger, C.G.; Dyson, P.J.; Davey, C.A. A ruthenium antimetastasis agent forms specific histone protein adducts in the nucleosome core. Chem. Eur. J. 2011, 17, 3562-3566.
50. Messori, L.; Orioli, P.; Vullo, D.; Alessio, E.; Iengo, E. A spectroscopic study of the reaction of NAMI, a novel ruthenium(III) anti-neoplastic complex, with bovine serum albumin. Eur. J. Biochem. 2000, 267, 1206-1213.
51. Bergamo, A.; Messori, L.; Piccioli, F.; Cocchietto, M.; Sava, G. Biological role of adduct formation of the ruthenium(III) complex NAMI-A with serum albumin and serum transferrin. Invest. New Drug 2003, 21, 401-411.
52. Piccioli, F.; Sabatini, S.; Messori, L.; Orioli, P.; Hartinger, C.G.; Keppler, B.K. A comparative study of adduct formation between the anticancer ruthenium(III) compound HInd trans-[RuCl4(Ind)2] and serum proteins. J. Inorg. Biochem. 2004, 98, 1135-1142.
53. Smith, C.A.; Sutherland-Smith, A.J.; Keppler, B.K.; Kratz, F.; Baker, E.N. Binding of ruthenium(III) anti-tumor drugs to human lactoferrin probed by high resolution X-ray crystallographic structure analyses. J. Biol. Inorg. Chem. 1996, 1, 424-431.
54. Casini, A.; Mastrobuoni, G.; Ang, W.H.; Gabbiani, C.; Pieraccini, G.; Moneti, G.; Dyson, P.J.; Messori, L. ESI-MS characterisation of protein adducts of anticancer ruthenium(II)-arene PTA (RAPTA) complexes. ChemMedChem 2007, 2, 631-635.
55. Hartinger, C.G.; Casini, A.; Duhot, C.; Tsybin, Y.O.; Messori, L.; Dyson, P.J. Stability of an organometallic ruthenium-ubiquitin adduct in the presence of glutathione: Relevance to antitumour activity. J. Inorg. Biochem. 2008, 102, 2136-2141.
56. Scolaro, C.; Chaplin, A.B.; Hartinger, C.G.; Bergamo, A.; Cocchietto, M.; Keppler, B.K.; Sava, G.; Dyson, P.J. Tuning the hydrophobicity of ruthenium(II)-arene (RAPTA) drugs to modify uptake, biomolecular interactions and efficacy. Dalton Trans. 2007, 43, 5065-5072.
57. Selvi, P.T.; Stoeckli-Evans, H.; Palaniandavar, M. Synthesis, structure and DNA interaction of cobalt (III) bis-complexes of 1,3-bis(2-pyridylimino)isoindoline and 1,4,7-triazacyclo-nonane. J. Inorg. Biochem. 2005, 99, 2110-2118.
58. Miller, S.A.; Dykes, D.D.; Polesky, H.F. A simple salting out procedure for extracting DNA from nucleated cells. Nucleic Acids Res. 1988, 16, 1215.